UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): August 13, 2009
 
 
 
NILE THERAPEUTICS, INC.
(Exact name of Registrant as Specified in its Charter)
 
         
Delaware
  
001-34058
  
88-0363465
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
 
4 West 4th, Suite 400
San Mateo, CA 94402
(Address of Principal Executive Offices)
 
(415) 875-7880
(Registrant’s telephone number, including area code)
 
115 Sansome Street, Suite 310
San Francisco, California 94104
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 2.02. Results of Operations and Financial Condition.
 
On August 13, 2009, Nile Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2009. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01.  Financial Statements and Exhibits.

(d)  Exhibits. The following exhibit is furnished herewith.

Exhibit No.
Description
   
99.1
Nile Therapeutics, Inc. press release dated August 13, 2009.

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 

 
 
NILE THERAPEUTICS, INC.
  
     
       
Date: August 17, 2009
By:
/s/ Daron Evans
  
   
Daron Evans
  
   
Chief Financial Officer
  


 

 
EXHIBIT INDEX
 
Description
   
99.1
Nile Therapeutics, Inc. press release dated August 13, 2009.